HRP20171898T1 - Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika - Google Patents

Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika Download PDF

Info

Publication number
HRP20171898T1
HRP20171898T1 HRP20171898TT HRP20171898T HRP20171898T1 HR P20171898 T1 HRP20171898 T1 HR P20171898T1 HR P20171898T T HRP20171898T T HR P20171898TT HR P20171898 T HRP20171898 T HR P20171898T HR P20171898 T1 HRP20171898 T1 HR P20171898T1
Authority
HR
Croatia
Prior art keywords
ribavirin
combination
daas
patient
use according
Prior art date
Application number
HRP20171898TT
Other languages
English (en)
Croatian (hr)
Inventor
Barry M. Bernstein
Sandeep Dutta
Wei Liu
Thomas J. PODSADECKI
Andrew L. Campbell
Rajeev M. Menon
Chih-Wei Lin
Tianli WANG
Walid M. Awni
Sven MENSING
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171898(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of HRP20171898T1 publication Critical patent/HRP20171898T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171898TT 2013-03-14 2014-03-14 Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika HRP20171898T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
EP14725812.3A EP2968302B9 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Publications (1)

Publication Number Publication Date
HRP20171898T1 true HRP20171898T1 (hr) 2018-04-06

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171898TT HRP20171898T1 (hr) 2013-03-14 2014-03-14 Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR20180045055A (enExample)
CN (3) CN108187056A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T3 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG10201709840UA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TW202002979A (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
TW202002979A (zh) * 2013-03-14 2020-01-16 美商艾伯維有限公司 治療hcv的方法
MX2016005393A (es) * 2013-10-25 2016-08-11 Abbvie Inc Metodos para tratar vhc.
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
AU2015240753B2 (en) * 2014-04-02 2020-01-16 Abbvie Inc. Methods for treating HCV
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN108778764B (zh) 2016-01-08 2020-09-04 恩图鲁斯特咨询卡有限公司 具有卡片返回路径的卡片印刷机构
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
AU2017332771A1 (en) * 2016-09-23 2019-04-04 Abbvie Inc. Dose adjustment
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
TW202012001A (zh) * 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009256623A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
ES2565536T3 (es) * 2009-06-11 2016-04-05 Abbvie Bahamas Ltd. Heterociclos trisustituidos como inhibidores de la replicación del virus de la Hepatitis C VHC
KR102163902B1 (ko) * 2010-09-21 2020-10-12 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
PH12014500832A1 (en) 2011-10-21 2022-12-02 Abbvie Inc Methods for treating hcv
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
TW202002979A (zh) * 2013-03-14 2020-01-16 美商艾伯維有限公司 治療hcv的方法

Also Published As

Publication number Publication date
EP2968302A1 (en) 2016-01-20
EP3733180A1 (en) 2020-11-04
PL2968302T4 (pl) 2018-04-30
CN108187056A (zh) 2018-06-22
HK1213191A1 (en) 2016-06-30
EP3915559A1 (en) 2021-12-01
JP6563894B2 (ja) 2019-08-21
RS56735B1 (sr) 2018-03-30
EP3318258B1 (en) 2020-05-13
WO2014152635A9 (en) 2014-12-11
CN105007921B (zh) 2018-12-11
EP2968302B1 (en) 2017-09-06
CN105007921A (zh) 2015-10-28
AU2014239322A1 (en) 2015-08-27
EA030482B1 (ru) 2018-08-31
MX2015012536A (es) 2016-01-12
IL240445B (en) 2019-07-31
CN109908353A (zh) 2019-06-21
AU2018202581A1 (en) 2018-05-10
SI2968302T1 (en) 2018-04-30
JP2019167347A (ja) 2019-10-03
SMT201800017T1 (it) 2018-03-08
JP2016513703A (ja) 2016-05-16
KR20180045055A (ko) 2018-05-03
HK1255257A1 (en) 2019-08-09
LT2968302T (lt) 2017-12-27
JP2019214585A (ja) 2019-12-19
BR112015020918A2 (pt) 2017-07-18
AU2018202581B2 (en) 2019-12-05
EP2968302B9 (en) 2019-02-13
HUE036069T2 (hu) 2018-06-28
ZA201705080B (en) 2019-02-27
EP3318258A1 (en) 2018-05-09
WO2014152635A1 (en) 2014-09-25
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
AU2020201656A1 (en) 2020-03-26
EA201890507A1 (ru) 2018-07-31
IL267927A (en) 2019-09-26
KR101853605B1 (ko) 2018-05-03
CY1121474T1 (el) 2020-05-29
NO3090119T3 (enExample) 2018-03-31
US20140274934A1 (en) 2014-09-18
CA2901818A1 (en) 2014-09-25
SG10201709840UA (en) 2018-01-30
CA2901818C (en) 2021-05-04
SG11201507361YA (en) 2015-10-29
TW201505633A (zh) 2015-02-16
PL2968302T3 (pl) 2018-04-30
EA201591701A1 (ru) 2016-02-29
KR20150129035A (ko) 2015-11-18
IL240445A0 (en) 2015-09-24
TW202002979A (zh) 2020-01-16
AU2014239322B2 (en) 2018-04-05
DK2968302T3 (en) 2017-12-18
ES2654109T3 (es) 2018-02-12

Similar Documents

Publication Publication Date Title
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
HRP20171036T1 (hr) Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c
JP2014530874A5 (enExample)
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
SI2709613T1 (en) Procedures for the treatment of HCV
JP2016513703A5 (enExample)
HK1199816A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
RU2015114543A (ru) Способы лечения гепатита с
RU2019114665A (ru) Противовирусные композиции для лечения инфекций, связанных с коронавирусами
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
MX388482B (es) Métodos para tratar el virus de la hepatitis c.
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
HRP20241221T1 (hr) POLICIKLIČNI KARBAMOILPIRIDONSKI DERIVATI ZA LIJEČENJE HIV-a
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
HK1255481A1 (zh) 用於治疗hcv的方法
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
RU2013105504A (ru) Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
EA201491652A1 (ru) Средство для лечения вирусного гепатита с
RU2014116988A (ru) Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection